You just read:

Novartis Drug PrJakavi® Associated with Significant Clinical Benefit for Patients with Debilitating and Life-threatening Blood Cancer Myelofibrosis

News provided by

Novartis Pharmaceuticals Canada Inc.

Mar 07, 2014, 05:59 ET